Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jul 16, 2019Aratana Reports Voting Results from 2019 Special Meeting of Stockholders
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting...
-
Jun 11, 2019Commercial availability of NOCITA 10 mL vial size anticipated by fall 2019
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the U.S. Food...
-
Jun 7, 2019Stockholders Elect All Class III Directors and Approve Proposals
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting...
-
May 8, 2019Continued revenue growth across portfolio of marketed pet therapeutics
Aratana recorded $7.4 million in total revenues for the first quarter of 2019, including $2.5 million in NOCITA net product sales, $1.5 million in ENTYCE net product sales and $3.4 million in licensing and collaboration revenue from Elanco for GALLIPRANT.
-
May 7, 2019
The Company plans on presenting at the Stifel Dental & Veterinary Conference on Wednesday, May 29, 2019 at 8:00 a.m. ET in New York City.
-
Apr 26, 2019Elanco announces formation of commercial team dedicated to veterinary specialty business
The Company announced it has signed an agreement to be acquired by Elanco Animal Health (NYSE: ELAN), its global collaboration partner on GALLIPRANT® (grapiprant tablets). In conjunction with the transaction, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business. If the proposed agreement is consummated, the Aratana field force would transition into this commercial team.
-
Mar 12, 2019
The Company announced its fourth quarter and full year 2018 financial results and recent business highlights.
-
Feb 13, 2019
The Company plans on attending several upcoming investment conferences, including Bank of America Merrill Lynch Animal Health Summit, Cowen Health Care Conference and Barclays Global Healthcare Conference.
-
Feb 12, 2019
The Company will host a live conference call on Tuesday, March 12, 2019 at 4:30 p.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2018.
-
Feb 4, 2019
The Company announced the appointment of Rhonda Hellums as Chief Financial Officer and Treasurer of Aratana effective February 1, 2019.
-
Jan 17, 2019
The Company announced today the Board of Directors has appointed Craig Tooman to serve as President and Chief Executive Officer of Aratana, and elected Tooman to the Board of Directors.
-
Nov 1, 2018
Aratana announced its third quarter 2018 financial results, reporting total net revenues of $21.6 million and net income of $8.8 million or $0.19 diluted earnings per share.
-
Oct 22, 2018
Aratana will host a live conference call on Friday, November 2, 2018 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2018.
-
Aug 29, 2018
The Company plans on presenting at CL King & Associates Best Ideas Conference on Thursday, September 13, 2018 at 1:15 p.m. ET in New York City.
-
Aug 2, 2018
Aratana announced its second quarter 2018 financial results, reporting total net revenues of $4.9 million and a net loss of $6.4 million or $0.14 diluted loss per share.
-
Jul 10, 2018
The Company will host a live conference call on Friday, August 3, 2018 at 8:30 a.m. ET to discuss financial results from the second quarter ended June 30, 2018.
-
Jun 1, 2018
Aratana submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) to expand the NOCITA label to include its use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy.
-
May 22, 2018
The Company plans on presenting at Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30 p.m. ET in New York City.
-
May 21, 2018
The Company has appointed Craig Barbarosh and Lowell Robinson to its Board of Directors in connection with a cooperation agreement with Engaged Capital, LLC.
-
May 3, 2018
Aratana announced its first quarter 2018 financial results, reporting total net revenues of $4.0 million and a net loss of $8.5 million or $0.19 diluted loss per share.
-
Apr 12, 2018
The Company will host a live conference call on Friday, May 4, 2018 at 8:30 a.m. ET to discuss financial results from the first quarter ended March 31, 2018.
-
Apr 5, 2018
Aratana confirmed it received a notice of nomination of three director candidates for election to the Company's Board of Directors from Engaged Capital, LLC and certain of its affiliated entities.
-
Mar 13, 2018
Aratana announced its fourth quarter and full year 2017 financial results, reporting total net revenues of $10.4 million and a net loss of $15.6 million or $0.37 diluted loss per share.
-
Mar 2, 2018
The Company plans on attending Cowen and Barclays investment conferences.
-
Mar 1, 2018
Aratana announced it licensed exclusive, worldwide rights to develop and commercialize AT-019 from AskAt Inc. AT-019 is a potent and innovative EP4 receptor antagonist with potential in pain, inflammation and other indications.
-
Feb 13, 2018
Aratana will host a live conference call on Wednesday, March 14, 2018 at 8:30 a.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2017.
-
Jan 18, 2018
Aratana announced GALLIPRANT® (grapiprant tablets) was named Animal Pharm's Best Companion Animal Product for 2017.
-
Jan 11, 2018
Together with Elanco, Aratana announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.
-
Dec 20, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced the...
-
Dec 15, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX) has received top-line pivotal field effectiveness study results for AT-016, an investigational adipose-derived allogeneic stem cell therapeutic candidate...
-
Nov 28, 2017
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats, today announced that it has...
-
Nov 27, 2017
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats, today announced that it is...
-
Nov 10, 2017
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Medicine Agency's (EMA) Committee for Medicinal...
-
Nov 2, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its third...
-
Oct 30, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, plans to present at...
-
Oct 13, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pet therapeutics, announced the Company is making...
-
Oct 5, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live...
-
Sep 18, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, plans to present at...
-
Aug 3, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its second...
-
Jul 26, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced positive...
-
Jul 18, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live...
-
May 16, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, plans to present at...
-
May 8, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its first...
-
May 3, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced that...
-
Apr 25, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Apr 24, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live...
-
Mar 13, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its fourth...
-
Mar 8, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Feb 22, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Feb 3, 2017Provides Update on Availability of ENTYCE® (capromorelin oral solution)
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jan 24, 2017Elanco launches first-in-class piprant for veterinary use
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), and Aratana Therapeutics, Inc. (NASDAQ: PETX) have announced veterinarians have a new targeted tool for the management of...
-
Jan 20, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Nov 3, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Oct 27, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Oct 19, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Oct 5, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Sep 21, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Aug 15, 2016Local Post-Operative Analgesia to Provide Extended Pain Control
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Aug 4, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jul 13, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jun 30, 2016Local Post-Operative Analgesia Provides Extended Pain Control
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jun 29, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jun 2, 2016Final Major Technical Section Complete Letter for NOCITA® (bupivacaine liposome injectable suspension)
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
May 23, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
May 17, 2016First-of-its-Kind Ghrelin Mimetic
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
May 5, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pharmaceutical products for companion animals,...
-
May 2, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Apr 25, 2016Conference Call Today at 6:00 p.m. ET
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals...
-
Apr 25, 2016Agreement to expand Elanco's companion animal portfolio, extend global reach of GALLIPRANT® (grapiprant tablets) in canine osteoarthritis therapy
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced that Elanco has licensed animal health rights to Aratana's...
-
Apr 14, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Mar 31, 2016AAHA Session to Highlight Galliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in Dogs
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Mar 22, 2016First-in-Class Ghrelin Agonist
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Mar 21, 2016Galliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in Dogs
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Mar 14, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Mar 2, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Feb 23, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Feb 23, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Feb 22, 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Feb 17, 2016EMA to Review Marketing Authorization Application for Therapeutic to Treat Pain and Inflammation in Dogs with Osteoarthritis
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jan 25, 2016Targeted Therapeutic Intended for Control of Pain and Inflammation in Dogs with Osteoarthritis
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Dec 15, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Nov 20, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Nov 13, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Nov 5, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Oct 29, 2015Conference Call and Webcast Scheduled for November 6, 2015 at 8:30 a.m. ET
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Oct 21, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals...
-
Oct 16, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Sep 24, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Aug 10, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Aug 6, 2015Pipeline continues to mature towards objective of six products being marketed in 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, announced...
-
Jul 30, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jul 27, 2015Provides additional details on AT-002 in dogs
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jul 22, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jul 21, 2015Conference Call and Webcast scheduled for August 7, 2015, 8:30 a.m. ET
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jul 14, 2015Commercialization anticipated in 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jun 26, 2015Commercialization Anticipated in 2016
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Jun 2, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
May 15, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
May 14, 2015Veterinary Industry Thought Leaders and Members of Aratana to Highlight Advances in the Treatment of Oncology, Inappetence and Pain for Pets
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
May 7, 2015-- Announces full-enrollment of two pivotal field effectiveness studies --
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, announced...